RNS Number : 5298E
Genedrive PLC
25 November 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

25 November 2026

genedrive plc

("**genedrive**", the "**Group**" or the "**Company**")

Direct Subscription to raise up to £1.23 million at 1.3 pence per share, representing a 72 per cent. premium to the latest share price

Manchester, UK – 25 November 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, is pleased to announce a direct subscription amounting to, in aggregate, £1.23 million by various existing and new investors including both David Nugent, a Director of the Company and the Company's largest shareholder, and Robert English, a substantial shareholder in the Company (**the "Subscription"**).

The Subscription utilises 94,615,386 new ordinary shares of £0.00015 each (**the "Subscription Shares"**) available to be issued for cash under the Company's existing authorities to issue and allot equity securities on a non-pre-emptive basis granted at the Company's AGM on 31 December 2025. The Company and the subscribers have agreed an issue price of 1.3 pence per Subscription Share representing a 72.4 per cent. premium to the Company's closing middle market share price on 24 November 2026.

The proceeds of the Subscription will provide additional working capital for the Group as it looks to accelerate commercial adoption of the Group's diagnostic tests.

Gino Miele, CEO of genedrive plc, said: *"This capital raise allows the Company to continue to accelerate the commercial adoption of its diagnostic tests in the UK and abroad. Further, completing the equity raise at a meaningful premium to genedrive's prevailing share price is a strong endorsement of the intrinsic value we are building and we very much welcome the participation of all investors in this subscription."*

David Nugent, Non Executive Director of genedrive plc, said: *"Over the past 10 months, the Company has adopted a different approach to financing, reflecting the Board's commitment to minimising dilution for existing shareholders and delivering long-term shareholder value. We are particularly pleased by the resolute level of support received in this fundraising and the significant premium at which subscribers have participated. On behalf of the Board, I would like to thank both the subscribers and our existing shareholders for their continued support."*

The Subscription

David Nugent, Robert English and a small number of other investors have agreed to subscribe for the Subscription Shares at the price of 1.3 pence per Subscription Share to raise an aggregate of £1.23 million through the Subscription. David Nugent has agreed to subscribe for 7,692,308 Subscription Shares at the

Issue Price to raise £0.1 million and Robert English has agreed to subscribe for 38,461,538 Subscriptions Shares at the Issue Price to raise £0.5 million. The other investors have agreed to subscribe for 48,461,540 Subscriptions Shares at the Issue Price to raise £0.63 million.

The Subscription Shares will be issued under the existing authority granted to the directors at the 2025 AGM to allot Shares free of pre-emption rights and the Subscription Shares are expected to be admitted to trading on AIM on 27 November 2026 ("**Admission**").

The Subscription Shares, when issued, will be credited as fully paid and will be identical and rank pari passu in all respects with the Company's then existing Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of such shares.

Related Party Transactions

David Nugent and Robert English are related parties of the Company pursuant to the AIM Rules and both of them being parties to the Subscription constitute related party transactions for the purposes of AIM Rule 13. The Directors (other than David Nugent) consider, having consulted with the Company's nominated adviser, Peel Hunt, that the Company entering into the Subscription with David Nugent and Robert English is fair and reasonable insofar as Shareholders are concerned.

The table below includes the anticipated aggregate beneficial shareholdings for David Nugent (and his connected parties) and Robert English (and his connected parties) as at the date of this Announcement and as expected to be at Admission.

Shareholder / Director	As at 25 November 2026	% of issued share capital	Immediately after Admission	% of enlarged issued share capital
David Nugent	401,500,000	25.01	409,192,308	24.07
Robert English	232,099,348	14.46	270,560,886	15.91

Total Voting Rights

It is expected that Admission of the Subscription Shares will become effective at 8.00 a.m. on 27 November 2026. Following Admission, the Company will have 1,700,183,642 Ordinary Shares of £0.00015 each in issue each with equal voting rights. No shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Navigate to our Interactive Investor hub here: https://investors.genedrive.com/link/PZ3d7y

genedrive plc +44 (0) 161 989 0245
Dr Gino Miele (CEO) https://investors.genedrive.com/s/e0025c
Russ Shaw (CFO)

Peel Hunt LLP – Nominated Adviser and Broker +44 (0) 20 7418 8900
James Steel (Investment Banking)

5654 & Company (Media & Investor Relations) genedrive@5654.co.uk

Matthew Neal	+44 (0)7917 800 011
Melissa Gardiner	+44 (0)7757 697 357
Lucy Featherstone	+44 (0)7474 953 578

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03

About genedrive plc (http://www.genedrive.com)
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	**Details of the person discharging managerial responsibilities / person closely associated**	
a)	Name	David Nugent
2	**Reason for the notification**	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	genedrive plc
b)	LEI	213800ZYODIRZ87Y4K14
4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.00015 each ISIN: GB00B1VKB244
b)	Nature of the transaction	Purchase of ordinary shares

<table>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>1.3p</td><td>7,692,308</td></tr></table></td></tr>
<tr><td>d)</td><td>Aggregated information
- Aggregated volume
- Price</td><td>
7,692,308
1.3p</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>25 November 2026</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>Outside of a trading venue</td></tr>
</table>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUSRORNRUAUUA